Glycine

Glycine

SCHEMBL290022

CCC[N+](C)(C)N.NCC(=O)[O-]

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
BBOX1 O75936 7/20 0.41
FFAR3 O14843 2/20 0.39
HDAC3 O15379 2/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC2 Q92769 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
CA1 P00915 1/20 0.34
CPT2 P23786 1/20 0.33
CPT1A P50416 1/20 0.33
SLC22A16 Q86VW1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL6039286 0.86 CA1 (0.40) BBOX1FFAR3HDAC3HDAC1HDAC2
L-Lactic Acid SCHEMBL27743481 0.78 TSHR (0.37) BBOX1FFAR3HDAC3HDAC1HDAC2
Tetramethylammonium Ion SCHEMBL9388139 0.77 CPT2 (0.42) BBOX1FFAR3HDAC3HDAC1HDAC2
SCHEMBL352085 0.77
Citric Acid SCHEMBL27511805 0.77 CA4 (0.55) BBOX1FFAR3HDAC3HDAC1HDAC2
Glycine SCHEMBL22529120 0.77 DNM1 (0.41)
Glycine SCHEMBL28653969 0.76 DNM1 (0.46) BBOX1FFAR3HDAC3HDAC1HDAC2
Tetramethylammonium Ion SCHEMBL28584696 0.75 CPT2 (0.41) BBOX1FFAR3HDAC3HDAC1HDAC2
Hydrochloric Acid SCHEMBL4850830 0.74
SCHEMBL1248453 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 558 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4366690-B1 POLYOL ESTER MIXTURE FOR USE AS VASELINE SUBSTITUTE BASF SE (DE) 2025-06-25 EP disclosed
US-20240390393-A1 BOTANICAL EXTRACTS AND COMPOUNDS FROM SCHINUS PLANTS AND METHODS OF USE EMORY UNIVERSITY (US) 2024-11-28 US disclosed
US-20240325268-A1 POLYOL ESTER MIXTURE FOR USE AS VASELINE SUBSTITUTE BASF SE (DE) 2024-10-03 US disclosed
US-20240307413-A1 BOTANICAL EXTRACTS AND COMPOUNDS FROM SCHINUS PLANTS AND METHODS OF USE EMORY UNIVERSITY (US) 2024-09-19 US disclosed
US-12083132-B1 Botanical extracts and compounds from Schinus plants and methods of use EMORY UNIVERSITY (US) 2024-09-10 US disclosed
EP-4366690-A1 POLYOL ESTER MIXTURE FOR USE AS VASELINE SUBSTITUTE BASF SE (DE) 2024-05-15 EP disclosed
EP-4308286-A1 ACTIVE SUBSTANCE CAPSULES Symrise AG (DE) 2024-01-24 EP disclosed
US-20230398057-A1 AGENT FOR DYEING KERATINUOS MATERIAL, COMPRISING AMINOSILICONE, A CHROMOPHORIC COMPOUND AND AN ADDITION PRODUCT OF C1-C6 ALKYLENE OXIDE(S) TO THE ESTERS OF FATTY ACIDS AND AROMATIC ALCOHOLS HENKEL AG & CO. KGAA (DE) 2023-12-14 US disclosed
US-11633407-B2 Botanical extracts and compounds from Schinus plants and methods of use EMORY UNIVERSITY (US) 2023-04-25 US disclosed
US-20230112887-A1 Pentagalloyl Glucose Derived from Schinus Plants and Methods of Use UNIV EMORY (US) 2023-04-13 US disclosed
WO-1997004740-A1 OXIDATION COLORANTS FOR DYEING KERATINIC FIBERS, CONTAINING A SPECIAL COMBINATION OF DEVELOPER COMPONENTS AND ALKALISATION AGENTS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1997-02-13 WO disclosed
WO-1997005224-A1 POURABLE NACREOUS LUSTRE CONCENTRATE HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1997-02-13 WO disclosed
EP-0737211-A1 CATIONIC BIOPOLYMERS HENKEL KGAA (DE) 1996-10-16 EP disclosed
WO-1996016991-A1 CATIONIC BIOPOLYMERS HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1996-06-06 WO disclosed
WO-1995034528-A1 POLYOLPOLYHYDROXYSTEARATES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1995-12-21 WO disclosed
EP-0519946-A1 SURFACE-ACTIVE MIXTURES Henkel Kommanditgesellschaft auf Aktien (DE) 1992-12-30 EP disclosed
WO-1991013960-A1 SURFACE-ACTIVE MIXTURES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1991-09-19 WO disclosed
WO-1990008531-A2 SURFACE ACTIVE MIXTURES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1990-08-09 WO disclosed
EP-0371339-A2 Surfactant mixtures Henkel Kommanditgesellschaft auf Aktien (DE) 1990-06-06 EP disclosed
EP-0337130-A2 Hair-treating device Henkel Kommanditgesellschaft auf Aktien (DE) 1989-10-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240325268-A1 POLYOL ESTER MIXTURE FOR USE AS VASELINE SUBSTITUTE FASN, DEGS1, ACSL1 BBOX1 1870/4885FFAR3 40/4885HDAC3 1534/4885
US-20240390393-A1 BOTANICAL EXTRACTS AND COMPOUNDS FROM SCHINUS PLANTS AND METHODS OF USE BROX, C5, SYMPK BBOX1 109/4885FFAR3 2546/4885HDAC3 1676/4885
US-12083132-B1 Botanical extracts and compounds from Schinus plants and methods of use BROX, C5, SYMPK BBOX1 109/4885FFAR3 2546/4885HDAC3 1676/4885
US-20230398057-A1 AGENT FOR DYEING KERATINUOS MATERIAL, COMPRISING AMINOSILICONE, A CHROMOPHORIC COMPOUND AND AN ADDITION PRODUCT OF C1-C6 ALKYLENE OXIDE(S) TO THE ESTERS OF FATTY ACIDS AND AROMATIC ALCOHOLS KRT18, C1S, FAM83E BBOX1 1398/4885FFAR3 163/4885HDAC3 1962/4885
US-20240307413-A1 BOTANICAL EXTRACTS AND COMPOUNDS FROM SCHINUS PLANTS AND METHODS OF USE BROX, C5, SYMPK BBOX1 109/4885FFAR3 2546/4885HDAC3 1676/4885
US-11633407-B2 Botanical extracts and compounds from Schinus plants and methods of use BROX, C5, SYMPK BBOX1 109/4885FFAR3 2546/4885HDAC3 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.